AU2010339882B2 - Abuse-resistant formulations - Google Patents

Abuse-resistant formulations Download PDF

Info

Publication number
AU2010339882B2
AU2010339882B2 AU2010339882A AU2010339882A AU2010339882B2 AU 2010339882 B2 AU2010339882 B2 AU 2010339882B2 AU 2010339882 A AU2010339882 A AU 2010339882A AU 2010339882 A AU2010339882 A AU 2010339882A AU 2010339882 B2 AU2010339882 B2 AU 2010339882B2
Authority
AU
Australia
Prior art keywords
hydromorphone
granules
ethylcellulose
coated
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010339882A
Other languages
English (en)
Other versions
AU2010339882A1 (en
Inventor
Ehab Hamed
Manuel A. Vega Zepeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of AU2010339882A1 publication Critical patent/AU2010339882A1/en
Application granted granted Critical
Publication of AU2010339882B2 publication Critical patent/AU2010339882B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010339882A 2009-12-17 2010-12-16 Abuse-resistant formulations Ceased AU2010339882B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28751509P 2009-12-17 2009-12-17
US61/287,515 2009-12-17
PCT/US2010/060755 WO2011084593A2 (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Publications (2)

Publication Number Publication Date
AU2010339882A1 AU2010339882A1 (en) 2012-07-05
AU2010339882B2 true AU2010339882B2 (en) 2016-10-27

Family

ID=43618139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010339882A Ceased AU2010339882B2 (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Country Status (10)

Country Link
US (2) US20120225122A1 (enExample)
EP (1) EP2512456A2 (enExample)
JP (1) JP5894717B2 (enExample)
CN (1) CN102665694A (enExample)
AU (1) AU2010339882B2 (enExample)
CA (1) CA2784407A1 (enExample)
IL (1) IL219961A (enExample)
MX (1) MX348361B (enExample)
NZ (1) NZ600640A (enExample)
WO (1) WO2011084593A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
EP2992825B1 (en) 2007-11-26 2017-11-01 C.R. Bard Inc. Integrated system for intravascular placement of a catheter
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
US9445734B2 (en) 2009-06-12 2016-09-20 Bard Access Systems, Inc. Devices and methods for endovascular electrography
WO2010144922A1 (en) 2009-06-12 2010-12-16 Romedex International Srl Catheter tip positioning method
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
EP2482719A4 (en) 2009-09-29 2016-03-09 Bard Inc C R STYLETS FOR USE WITH APPARATUS FOR INTRAVASCULAR PLACEMENT OF A CATHETER
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
US10639008B2 (en) 2009-10-08 2020-05-05 C. R. Bard, Inc. Support and cover structures for an ultrasound probe head
BR112012019354B1 (pt) 2010-02-02 2021-09-08 C.R.Bard, Inc Método para localização de um dispositivo médico implantável
WO2011150376A1 (en) 2010-05-28 2011-12-01 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
CA2800810C (en) 2010-05-28 2019-11-05 C.R. Bard, Inc. Insertion guidance system for needles and medical components
WO2012024577A2 (en) 2010-08-20 2012-02-23 C.R. Bard, Inc. Reconfirmation of ecg-assisted catheter tip placement
WO2012058461A1 (en) 2010-10-29 2012-05-03 C.R.Bard, Inc. Bioimpedance-assisted placement of a medical device
CA2835890A1 (en) 2011-07-06 2013-01-10 C.R. Bard, Inc. Needle length determination and calibration for insertion guidance system
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
US20150086626A1 (en) * 2012-04-17 2015-03-26 Mylan, Inc Stable dosage forms of skeletal muscle relaxants with extended release coating
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
EP2893928B1 (en) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2811323T3 (es) 2014-02-06 2021-03-11 Bard Inc C R Sistemas para el guiado y la colocación de un dispositivo intravascular
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3852622B1 (en) 2018-10-16 2025-04-02 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
WO2020112699A1 (en) 2018-11-26 2020-06-04 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035474A1 (en) * 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2572491A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
ATE455538T1 (de) * 2007-11-09 2010-02-15 Acino Pharma Ag Retardtabletten mit hydromorphon
CA2798702A1 (en) * 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035474A1 (en) * 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation

Also Published As

Publication number Publication date
NZ600640A (en) 2014-11-28
IL219961A (en) 2017-06-29
MX348361B (es) 2017-06-07
CA2784407A1 (en) 2011-07-14
AU2010339882A1 (en) 2012-07-05
US20140294953A1 (en) 2014-10-02
CN102665694A (zh) 2012-09-12
WO2011084593A2 (en) 2011-07-14
WO2011084593A3 (en) 2012-03-29
EP2512456A2 (en) 2012-10-24
IL219961A0 (en) 2012-07-31
US9474721B2 (en) 2016-10-25
US20120225122A1 (en) 2012-09-06
MX2012006829A (es) 2012-07-10
JP5894717B2 (ja) 2016-03-30
JP2013514386A (ja) 2013-04-25

Similar Documents

Publication Publication Date Title
AU2010339882B2 (en) Abuse-resistant formulations
AU2011220813B2 (en) Abuse-resistant formulations
CA2699142C (en) Abuse resistant drug formulation
US8445018B2 (en) Abuse resistant drug formulation
AU2011253216B2 (en) Alcohol-resistant formulations
JP2009543791A (ja) 即放性形態および徐放性形態のトラマドールを有するマルチパーティキュレート処方物
US8927025B2 (en) Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US20130171256A1 (en) Alcohol-resistant extended release dosage forms comprising venlafaxine
HK1176885B (en) Abuse-resistant formulations
HK1176885A (en) Abuse-resistant formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired